JP7350759B2 - ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体 - Google Patents

ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体 Download PDF

Info

Publication number
JP7350759B2
JP7350759B2 JP2020544648A JP2020544648A JP7350759B2 JP 7350759 B2 JP7350759 B2 JP 7350759B2 JP 2020544648 A JP2020544648 A JP 2020544648A JP 2020544648 A JP2020544648 A JP 2020544648A JP 7350759 B2 JP7350759 B2 JP 7350759B2
Authority
JP
Japan
Prior art keywords
phenyl
triazinane
trione
phenoxyphenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020544648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514963A5 (cg-RX-API-DMAC7.html
JP2021514963A (ja
Inventor
グンナル ノードバル,
ポントゥス フォシェル,
Original Assignee
アルゼキュア ファーマ アーべー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1810667.4A external-priority patent/GB201810667D0/en
Application filed by アルゼキュア ファーマ アーべー filed Critical アルゼキュア ファーマ アーべー
Publication of JP2021514963A publication Critical patent/JP2021514963A/ja
Publication of JP2021514963A5 publication Critical patent/JP2021514963A5/ja
Application granted granted Critical
Publication of JP7350759B2 publication Critical patent/JP7350759B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • C07D251/34—Cyanuric or isocyanuric esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020544648A 2018-02-26 2019-02-26 ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体 Active JP7350759B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1850217-9 2018-02-26
SE1850217 2018-02-26
GB1810667.4 2018-06-28
GBGB1810667.4A GB201810667D0 (en) 2018-06-28 2018-06-28 New compounds and uses
PCT/GB2019/050523 WO2019162702A1 (en) 2018-02-26 2019-02-26 Triazine derivatives for treating diseases relating to neurotrophins

Publications (3)

Publication Number Publication Date
JP2021514963A JP2021514963A (ja) 2021-06-17
JP2021514963A5 JP2021514963A5 (cg-RX-API-DMAC7.html) 2022-03-07
JP7350759B2 true JP7350759B2 (ja) 2023-09-26

Family

ID=65729389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544648A Active JP7350759B2 (ja) 2018-02-26 2019-02-26 ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体

Country Status (24)

Country Link
US (3) US11352332B2 (cg-RX-API-DMAC7.html)
EP (1) EP3759088B8 (cg-RX-API-DMAC7.html)
JP (1) JP7350759B2 (cg-RX-API-DMAC7.html)
KR (1) KR102782749B1 (cg-RX-API-DMAC7.html)
CN (1) CN111819172B (cg-RX-API-DMAC7.html)
AU (1) AU2019223333B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017341A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090864A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002157A1 (cg-RX-API-DMAC7.html)
DK (1) DK3759088T3 (cg-RX-API-DMAC7.html)
ES (1) ES2941529T3 (cg-RX-API-DMAC7.html)
FI (1) FI3759088T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230290T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061751T2 (cg-RX-API-DMAC7.html)
IL (1) IL276624B2 (cg-RX-API-DMAC7.html)
LT (1) LT3759088T (cg-RX-API-DMAC7.html)
MA (1) MA52415A (cg-RX-API-DMAC7.html)
MX (1) MX2020008816A (cg-RX-API-DMAC7.html)
PL (1) PL3759088T3 (cg-RX-API-DMAC7.html)
PT (1) PT3759088T (cg-RX-API-DMAC7.html)
SG (1) SG11202007136VA (cg-RX-API-DMAC7.html)
SI (1) SI3759088T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019162702A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202004220B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022546014A (ja) * 2019-08-29 2022-11-02 アルゼキュア ファーマ アーべー ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11529819B2 (en) * 2017-06-08 2022-12-20 Nippon Soda Co., Ltd. Recording material and compound
US11352332B2 (en) 2018-02-26 2022-06-07 AlzeCure Pharma AB Triazine derivatives for treating diseases relating to neurotrophins
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
WO2021259224A1 (zh) * 2020-06-23 2021-12-30 沈阳中化农药化工研发有限公司 三嗪苯甲酸酯类化合物及其应用
CN113831298B (zh) * 2020-06-23 2023-12-01 沈阳中化农药化工研发有限公司 光活性羧酸酯类化合物及其应用
CN113831299B (zh) * 2020-06-23 2023-12-01 沈阳中化农药化工研发有限公司 苯甲酸酯类化合物及其应用
WO2022203395A1 (ko) * 2021-03-23 2022-09-29 한국과학기술연구원 신규한 화합물 및 이를 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
CN118216517B (zh) * 2022-12-21 2025-06-24 沈阳中化农药化工研发有限公司 一种除草组合物及其应用
WO2025232990A1 (en) 2024-05-09 2025-11-13 AlzeCure Pharma AB Triazinone derivatives for use in the treatment of inflammation

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246109A1 (de) * 1972-09-20 1974-03-28 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazinderivate, ein verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2313721A1 (de) * 1973-03-20 1974-10-03 Bayer Ag Neue 1-phenylsubstituierte 1,3,5triazine, verfahren zu ihrer herstellung, sowie ihre verwendung als arzneimittel
DE2413722C3 (de) * 1974-03-21 1982-04-08 Bayer Ag, 5090 Leverkusen Neue 1-(4-Phenoxy-phenyl)-1,3,5-triazin-Derivate, ein Verfahren zu ihrer Herstellung sowie ihre Anwendung als Arzneimittel
DE2718799A1 (de) 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
EP0081142B1 (de) 1981-12-03 1986-06-25 BASF Aktiengesellschaft 1,3,5-Triazinone, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
DE3314739A1 (de) 1983-04-23 1984-10-25 Bayer Ag, 5090 Leverkusen 1-(4-(4-(fluoralkylmethylthio- oder -sulfinyl- oder -sulfonyl-)phenoxy) phenyl)-1,3,5-triazin-2,4,6(1h,3h,5h)-trione, verfahren zu ihrer herstellung und ihre verwendung als coccidiosemittel
DE3408768A1 (de) * 1984-03-09 1985-09-12 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
DE3516632A1 (de) 1985-05-09 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 1,3,5-triazintrionen
DE3516631A1 (de) 1985-05-09 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 3-methyl-1,3,5-triazintrionen
DE3703105A1 (de) 1987-02-03 1988-08-11 Bayer Ag Mittel gegen protozoen bei insekten
DE3810080A1 (de) 1988-03-25 1989-10-05 Bayer Ag Trisubstituierte 1,3,5-triazin-2,4,6-trione
DE3814323A1 (de) 1988-04-28 1989-11-09 Hoechst Ag Wasserloesliche zubereitungen von coccidiostatica
US4933341A (en) 1988-10-08 1990-06-12 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
DE4000624A1 (de) 1990-01-11 1991-07-18 Bayer Ag Fungizide verwendung von trisubstituierten 1,3,5-triazin-2,4,6-trionen, neue trisubstituierte 1,3,5-triazin-2,4,6-trione und verfahren zu ihrer herstellung
DE4329096A1 (de) 1993-08-30 1995-03-02 Bayer Ag Heterocyclylbenzoheterocyclen
US5519133A (en) 1995-06-02 1996-05-21 American Cyanamid Co. 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
CZ146296A3 (en) 1995-06-02 1997-04-16 American Cyanamid Co 3-(3-aryloxyphenyl)-1-(substituted methyl)-s-triazine-2,4,6-oxo or thiotriones, process of their preparation and herbicidal agents
US5604180A (en) 1995-06-02 1997-02-18 Crews, Jr.; Alvin D. 3-(3-aryloxyphenyl)-1 (substituted methyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
US5726126A (en) 1995-06-02 1998-03-10 American Cyanamid Company 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents
US5679791A (en) 1996-07-25 1997-10-21 American Cyanamid Company 1-(3-heterocyclylphenyl)-s-triazine-2,4,6-oxo or thiotrione herbicidal agents
HK1043019B (zh) 1998-10-08 2005-05-13 高新研究公司 用於预防和治疗原虫病的组合物和方法
HUP0104716A3 (en) 1998-12-22 2003-10-28 Bayer Corp Pittsburgh Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma and medicaments containing them
DE19937500A1 (de) 1999-08-09 2001-02-15 Bayer Ag Substituierte Heterocyclylbenzofurane
DE19958388A1 (de) 1999-12-03 2001-06-07 Bayer Ag Triazinonverbindungen zur Behandlung von durch den Befall mit parasitischen Protozoen bedingten Krankheiten
US6444615B1 (en) 2000-04-18 2002-09-03 Dow Agrosciences Llc Herbicidal imidazolidinetrione and thioxo-imidazolidinediones
DE10034800A1 (de) 2000-07-18 2002-01-31 Bayer Ag Substituierte Benzostickstoffheterocyclen
DE10040174A1 (de) 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen
DE10040110A1 (de) 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfoxiden zur Bekämpfung von Coccidiosen
AU2002324586B2 (en) 2001-08-02 2008-04-24 Neurocrine Biosciences, Inc. 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
EP1437344A4 (en) 2001-09-28 2006-09-20 Takeda Pharmaceutical BENZENE DERIVATIVES AND PROCESS FOR THE PREPARATION AND USE THEREOF
US6861523B2 (en) 2002-02-08 2005-03-01 Torrey Pines Institute For Molecular Studies 1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries
BR0304925A (pt) 2002-05-30 2004-09-28 Solvay Pharm Bv Compostos, composições farmacêuticas, e, uso dos compostos
AU2003251010A1 (en) 2002-07-15 2004-02-02 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
DE102006038292A1 (de) 2006-08-16 2008-02-21 Bayer Healthcare Ag Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen
WO2008148008A1 (en) 2007-05-23 2008-12-04 Emory University High throughput bioassay for identifying selective trka receptor agonists, and gambogic amide, a selective trka agonist with neuroprotective activity
US20120004310A1 (en) 2010-05-28 2012-01-05 Longo Frank M Non-peptide bdnf neurotrophin mimetics
US9828330B2 (en) 2013-03-15 2017-11-28 Pharmatrophix, Inc. Non-peptide BDNF neurotrophin mimetics
RU2016131875A (ru) 2014-01-20 2018-02-26 Ф. Хоффманн-Ля Рош Аг Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы
CN117137048A (zh) 2014-12-10 2023-12-01 马斯公司 风味组合物、包含该组合物的食品及增加食品鲜味味道强度的方法
EP3558320A1 (en) 2016-12-21 2019-10-30 Alzecure Pharma AB Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases
US11352332B2 (en) 2018-02-26 2022-06-07 AlzeCure Pharma AB Triazine derivatives for treating diseases relating to neurotrophins
GB201810669D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201912404D0 (en) 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022546014A (ja) * 2019-08-29 2022-11-02 アルゼキュア ファーマ アーべー ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体

Also Published As

Publication number Publication date
US20220306589A1 (en) 2022-09-29
LT3759088T (lt) 2023-05-10
WO2019162702A1 (en) 2019-08-29
PT3759088T (pt) 2023-04-10
CN111819172B (zh) 2024-02-06
EP3759088B1 (en) 2023-01-25
AU2019223333A1 (en) 2020-08-27
CN111819172A (zh) 2020-10-23
US11352332B2 (en) 2022-06-07
JP2021514963A (ja) 2021-06-17
KR102782749B1 (ko) 2025-03-18
DK3759088T3 (en) 2023-03-27
US20250214948A1 (en) 2025-07-03
CL2020002157A1 (es) 2020-12-18
EP3759088A1 (en) 2021-01-06
IL276624B1 (en) 2023-06-01
CA3090864A1 (en) 2019-08-29
ZA202004220B (en) 2023-12-20
MA52415A (fr) 2021-01-06
HUE061751T2 (hu) 2023-08-28
ES2941529T3 (es) 2023-05-23
KR20200126988A (ko) 2020-11-09
RU2020126542A (ru) 2022-03-29
HRP20230290T1 (hr) 2023-05-26
IL276624B2 (en) 2023-10-01
EP3759088B8 (en) 2023-03-08
BR112020017341A2 (pt) 2020-12-15
PL3759088T3 (pl) 2023-07-03
IL276624A (en) 2020-09-30
SI3759088T1 (sl) 2023-07-31
MX2020008816A (es) 2020-09-28
US20200399230A1 (en) 2020-12-24
SG11202007136VA (en) 2020-08-28
FI3759088T3 (fi) 2023-04-05
AU2019223333B2 (en) 2024-06-20
US12209071B2 (en) 2025-01-28

Similar Documents

Publication Publication Date Title
KR102782749B1 (ko) 뉴로트로핀과 관련된 질병을 치료하기 위한 트리아진 유도체
CN108779096B (zh) 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途
JP2016504282A (ja) ジヒドロピラゾールgpr40モジュレーター
CN112513032B (zh) 作为trk受体的调节剂的4-取代的苯基-1,3,5-三嗪衍生物
KR20190098982A (ko) 트리아진트리온 유도체 및 뉴로트로핀 수용체 및 수용체 티로신 키나제의 조절제로서의 이의 용도
KR102962516B1 (ko) 뉴로트로핀에 관련된 질환의 치료를 위한 트리아진 유도체
US10519105B2 (en) KCNQ2-5 channel activator
KR20210028649A (ko) Trk 수용체의 조절제로서의 4-치환된 페닐-1,3,5-트리아진 유도체
RU2816837C2 (ru) Производные триазина для лечения заболеваний, связанных с нейротрофинами
HK40033844A (en) Triazine derivatives for treating diseases relating to neurotrophins
HK40033844B (en) Triazine derivatives for treating diseases relating to neurotrophins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230913

R150 Certificate of patent or registration of utility model

Ref document number: 7350759

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150